Fludarabine Inhibits DNA Replication: A Rationale for Its Use in the Treatment of Acute Leukemias

References

• Montgomery J. A., Hewson K. Nucleosides of 2-fluo-roadenine. J. Med. Chem. 1969; 12: 498–504
   PubMed Web of Science ®Google Scholar
• Malspeis L., Grever M. R., Staubus A. E., et al. Pharmacokinetics of 2-Fara-A (9-β-D-arabinofuranosyl-2-fluo-roadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. Semin. Oncol. 1990; 17(Suppl. 8)18–32
   PubMedGoogle Scholar
• Danhauser L., Plunkett W., Keating M., et al. 9-β-D-ara-binofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother. Pharmacol. 1986; 18: 145–152
   PubMed Web of Science ®Google Scholar
• Plunkett W., Huang P., Gandhi V. Metabolism and action of fludarabine phosphate. Semin. Oncol. 1990; 17(Suppl. 8)3–17
   PubMed Web of Science ®Google Scholar
• Plunkett W., Saunders P. P. Metabolism and action of purine nucleoside analogs. Pharmacol. Ther. 1991; 49: 239–268
   PubMed Web of Science ®Google Scholar
• Plunkett W., Gandhi V. Cellular metabolism of nucleoside analogs in CLL: Implications for drug development. Chronic Lymphocytic Leukemia. Scientific Advances and Clinical Developments, E. Cheson. Marcel Dekker, Inc., New York 1992; 197–219
   Google Scholar
• Kemena A., Gandhi V., Shewach D. S., et al. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy. Cancer Chemother. Pharmacol. 1992; 31: 193–199
   PubMed Web of Science ®Google Scholar
• Gandhi V., Estey E., Keating M. J., et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J. Clin. Oncol. 1993; 11: 116–124
   PubMed Web of Science ®Google Scholar
• Gandhi V., Kemena A., Keating M. J., et al. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leukemia Lymphoma 1993; 10: 49–56
   PubMed Web of Science ®Google Scholar
• Plunkett W., Gandhi V., Huang P., et al. Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin. Oncol. 1993; 20: 2–12
   PubMed Web of Science ®Google Scholar
• Spyrou G., Reichard P. Intracellular compartmentation of deoxycytidine nucleotide pools in S phase mouse 3T3 fibroblasts. J. Biol. Chem. 1989; 264: 960–964
   PubMed Web of Science ®Google Scholar
• Thelander L., Reichard P. Reduction of ribonucleotides. Ann. Rev. Biochem. 1979; 48: 133–158
   PubMed Web of Science ®Google Scholar
• Reichard P. Interactions between deoxyribonucleotides and DNA synthesis. Ann. Rev. Biochem. 1988; 57: 349–374
   PubMed Web of Science ®Google Scholar
• Cory J. G., Carter G. L. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors. Cancer Res. 1988; 48: 839–843
   PubMed Web of Science ®Google Scholar
• White E. L., Shaddix S. C., Brockman R. W., et al. Comparison of the actions of 9-β-D-arabinofuranosyl-2-fluoroade-nine and 9-β-arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res. 1982; 42: 2260–2264
   PubMed Web of Science ®Google Scholar
• Tseng W-C., Derse D., Cheng Y-C., et al. In vitro biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol. Pharmacol 1982; 21: 474–477
   PubMed Web of Science ®Google Scholar
• Sato A., Montgomery J. A., Cory J. G. Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides and hydroxyurea or 2,3-dihydro-IH-pyrazole[2,3-a]imidazole. Cancer Res. 1984; 44: 3286–3290
   PubMed Web of Science ®Google Scholar
• Parker W. B., Bapat A. R., Shen J-X., et al. Interaction of 2-halogenated dATP analogs (F, CI, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol. Pharmacol 1988; 34: 485–491
   PubMed Web of Science ®Google Scholar
• Parker W. B., Shaddix S. C., Chang C-H., et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res. 1991; 51: 2386–2394
   PubMed Web of Science ®Google Scholar
• Gandhi V., Plunkett W. Modulation of arabinosylnu-cleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988; 48: 329–334
   PubMed Web of Science ®Google Scholar
• Huang P. Metabolism and action of 9-β-D-arabinofura-nosyl-2-fluoroadenine. The University of Texas, Houston, Texas 1990
   Google Scholar
• Chang C-H., Derse D., Cheng Y-C., et al. “Self-Potentiation” mechanism of action for 9-β-D-arabinofuranosyl-2-fluoroadenine. Fed. Proc 1981; 98: 2497
   Google Scholar
• Grant S. Biochemical modulation of cytosine arabinoside. Pharmacol. Ther. 1990; 48: 29–44
   PubMed Web of Science ®Google Scholar
• Huang P., Chubb S., Plunkett W. Termination of DNA synthesis of 9-β-D-arabinofuranosyl-2-fluoroadenine: A mechanism for cytotoxicity. J. Biol. Chem. 1990; 265: 16617–16625
   PubMed Web of Science ®Google Scholar
• Townsend A., Cheng Y-C. Sequence-specific effects of ara-5-aza-CTP and ara-CTP on DNA synthesis by purified human DNA polymerases in vitro: Visualization of chain elongation on a defined template. Mol. Pharmacol. 1987; 32: 330–339
   PubMed Web of Science ®Google Scholar
• Liu L. F. DNA topoisomerase poisons as antitumor drugs. Ann. Rev. Biochem. 1989; 58: 351–375
   PubMed Web of Science ®Google Scholar
• Liu S-Y., Hwang B-D., Liu Z-C., et al. Interaction of several nucleoside triphosphate analogs and 10-hydroxycamptothecin with human DNA topoisomerases. Cancer Res. 1989; 49: 1366–1370
   PubMed Web of Science ®Google Scholar
• Matson S. W., Kaiser-Rogers K. A. DNA helicases. Ann. Rev. Biochem. 1990; 59: 289–329
   PubMed Web of Science ®Google Scholar
• Roth Y-F. Eucaryotic primase. Eur. J. Biochem. 1987; 165: 473–481
   PubMedGoogle Scholar
• De Pamphilis M. Eukaryotic DNA replication: Anatomy of an origin. Ann. Rev. Biochem. 1993; 62: 29–64
   PubMed Web of Science ®Google Scholar
• Parker W., Cheng Y-C. Inhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogs. Mol. Pharmacol. 1987; 31: 146–151
   PubMed Web of Science ®Google Scholar
• Catapano C. V., Chandler K. B., Fernandes D. J. Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate. Cancer Res. 1991; 51: 1829–1835
   PubMed Web of Science ®Google Scholar
• Catapano C. V., Perrino F. W., Fernandes D. J. Primer RNA chain termination induced by 9-β-D-arabinofuranosyl-2-flu-oroadenine 5′-triphosphate. A mechanism of DNA synthesis inhibition. J. Biol. Chem. 1993; 268: 7179–7185
   PubMed Web of Science ®Google Scholar
• Plunkett W., Chubb S., Alexander L., et al. Comparison of the toxicity and metabolism of 9-β-D-arabinofuranosyl-2-fluoroad-enine and 9-β-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res. 1980; 40: 2349–2355
   PubMed Web of Science ®Google Scholar
• Spriggs D., Robbins G., Mitchell T., et al. Incorporation of 9-β-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA. Biochem. Pharmacol. 1986; 35: 247–252
   PubMed Web of Science ®Google Scholar
• Echols H. Fidelity mechanisms in DNA replication. Ann. Rev. Biochem. 1991; 60: 477–511
   PubMed Web of Science ®Google Scholar
• Kamiya K., Huang P., Plunkett W. Excision of incorporated fludarabine from DNA by human DNA polymerase ϵ. Proc. Am. Assoc. Cancer Res. 1993; 34: 349, abstract
   Google Scholar
• Lindahl T., Barnes D. E. Mammalian DNA ligases. Ann. Rev. Biochem. 1992; 61: 251–281
   PubMed Web of Science ®Google Scholar
• Yang S-W., Huang P., Plunkett W., et al. Dual mode of inhibition of purified DNA ligase I from human cells by 9-β-D-ara-binofuranosyl-2-fluoroadenine triphosphate. J. Biol. Chem. 1992; 267: 2345–2349
   PubMed Web of Science ®Google Scholar
• Warrell R. P., Berman E. Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity. J. Clin. Oncol. 1986; 4: 74–79
   PubMed Web of Science ®Google Scholar
• Chun H. G., Leyland-Jones B. R., Caryk S. M., et al. Central nervous system toxicity of fludarabine phosphate. Cancer Treat. Rep. 1986; 70: 1225–1228
   PubMedGoogle Scholar
• Spriggs D. R., Stopa E., Mayer R. J., et al. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study. Cancer Res. 1986; 46: 5953–5958
   PubMed Web of Science ®Google Scholar
• Ellison R. R., Holland J. F., Weil M., et al. Arabinosyl cytosine: A useful agent in the treatment of acute leukemia in adults. Blood 1968; 32: 507–523
   PubMed Web of Science ®Google Scholar
• Suki S., Kantarjian H., Gandhi V., et al. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer 1993; 72: 2155–2160
   PubMed Web of Science ®Google Scholar
• Gandhi V. Fludarabine for treatment of adult acute myelogenous leukemia. Leukemia Lymphoma 1993; 11(Suppl. 5)1–7
   Google Scholar
• Keating M. J., Kantarjian H., Talpaz M., et al. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25
   PubMed Web of Science ®Google Scholar
• Gandhi V., Estey E., Keating M. J., et al. Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leukemia Lymphoma 1993; 10(Suppl.)109–114
   PubMedGoogle Scholar
• Estey E., Plunkett W., Gandhi V., et al. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leukemia Lymphoma 1993; 4: 343–350
   Web of Science ®Google Scholar
• Estey E., Gandhi V., Keating M. J., et al. G-CSF potentiates clinical and pharmacokinetic response to fludarabine and ara-C in AML and MDS. Proc. Am. Soc. Clin. Oncol. 1993; 12: 301, abstract
   Google Scholar